Efficacy and safety of degarelix in Korean patients with prostate cancer requiring androgen deprivation therapy: Open-label multicenter phase III study

PURPOSE: To assess the noninferiority, efficacy, and safety of degarelix in achieving and maintaining testosterone at castrate levels (≤0.5 ng/mL) in Korean patients (CS42) versus non-Asian patients with prostate cancer (PCa). METHODS: A Phase III, open-label, multicenter, single-arm trial was condu...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Dalsan, Chung, Byung Ha, Lee, Sang Eun, Kim, Choung-Soo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494635/
https://www.ncbi.nlm.nih.gov/pubmed/26157762
http://dx.doi.org/10.1016/j.prnil.2015.02.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494635/
https://www.ncbi.nlm.nih.gov/pubmed/26157762
http://dx.doi.org/10.1016/j.prnil.2015.02.005

Ejemplares similares